TRANSLATE

The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

Indolent B-cell lymphomas

This group includes indolent lymphomas, such as follicular lymphoma (FL) and marginal zone lymphoma (MZL). These have a more protracted clinical course, and many patients may not require intensive treatment in the beginning of their disease. In some patients, however, FL may transform into a more aggressive form that resembles diffuse large B-cell lymphoma (DLBCL) (FL Grade 3b).

Indolent B-cell lymphomas

Filter by content:

All Subtypes